[{"id":"8ab9b326-945d-42b1-83a2-bd1ce3110fd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03180528","created_at":"2021-01-18T15:41:05.915Z","updated_at":"2024-07-02T16:36:29.416Z","phase":"Phase 2","brief_title":"Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer","source_id_and_acronym":"NCT03180528","lead_sponsor":"Kavita Sarin","biomarkers":" STAT3 • GLI1","pipe":"","alterations":" ","tags":["STAT3 • GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e remetinostat (SHP-141)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 07/07/2018","start_date":" 07/07/2018","primary_txt":" Primary completion: 07/07/2020","primary_completion_date":" 07/07/2020","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2021-06-08"}]